Healthcare
Rigel Pharmaceuticals, Inc.(RIGL)
Live Price
Offline$32.91
-1.38% today
1Y Change
+76.28%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $540.00M
- Revenue Growth
- +64.1%
- EPS Growth
- +1960.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rigel Pharmaceuticals, Inc. (RIGL) is a Healthcare stock with a market cap of $540.00M and listed on NASDAQ. The stock last traded around $32.91 and up 76.3% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +64.1%, EPS growth of +1960.6%, a dividend yield of 0.0%. What stands out right now is revenue +64.1%, EPS +1960.6%, free cash flow +143.5% with operating margin 42.6% and ROIC 28.2%. Valuation is more restrained than many high-expectation growth names at P/E 1.4 and price/sales 1.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines RIGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+64.1% vs +7.6% peer median
Operating Margin
Above sector median
+42.6% vs +19.4% peer median
P/E
Below sector median
1.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +64.1% and EPS at +1960.6%, with operating margin around 42.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -5.1% | +4.6% | +7.9% |
2026 Mar 3, 2026 | -14.3% | -10.3% | -13.9% | -18.1% |
2025 Nov 4, 2025 | +57.0% | +33.4% | +33.7% | +66.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RIGL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RIGL Max Drawdown
-50.08%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RIGL and SPY.
Company Overview
Rigel Pharmaceuticals, Inc.
NASDAQ Global Select
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
- Leadership
- Raul R. Rodriguez
- IPO Date
- Nov 29, 2000
- Employees
- 162
- Street Address
- 1180 Veterans Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 624 1100
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 1.4
- EV/EBITDA
- 4.3
- Price/Sales
- 1.8
- Price/Book
- 1.4
Growth
- Revenue
- +64.1%
- EPS
- +1960.6%
- Free Cash Flow
- +143.5%
Profitability
- Gross Margin
- 93.3%
- Operating Margin
- 42.6%
- Net Margin
- 124.7%
- ROE
- 240.8%
- ROIC
- 28.2%
Balance Sheet
- Debt/Equity
- 0.14
- Current Ratio
- 2.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.